X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs BIOCON LTD - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. BIOCON LTD FRESENIUS KABI ONCO./
BIOCON LTD
 
P/E (TTM) x 22.1 92.4 24.0% View Chart
P/BV x 3.1 7.8 39.8% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 FRESENIUS KABI ONCO.   BIOCON LTD
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
BIOCON LTD
Mar-18
FRESENIUS KABI ONCO./
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1761,188 14.8%   
Low Rs79305 25.7%   
Sales per share (Unadj.) Rs37.768.7 54.8%  
Earnings per share (Unadj.) Rs5.17.6 67.4%  
Cash flow per share (Unadj.) Rs6.714.0 48.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs42.586.3 49.3%  
Shares outstanding (eoy) m158.23600.00 26.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.410.9 31.1%   
Avg P/E ratio x25.098.9 25.3%  
P/CF ratio (eoy) x18.953.4 35.4%  
Price / Book Value ratio x3.08.6 34.6%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m20,135447,900 4.5%   
No. of employees `0001.26.1 18.7%   
Total wages/salary Rs m7039,311 7.6%   
Avg. sales/employee Rs Th5,176.26,705.8 77.2%   
Avg. wages/employee Rs Th610.41,514.2 40.3%   
Avg. net profit/employee Rs Th699.6736.9 94.9%   
INCOME DATA
Net Sales Rs m5,96341,234 14.5%  
Other income Rs m182,062 0.9%   
Total revenues Rs m5,98143,296 13.8%   
Gross profit Rs m1,4308,291 17.2%  
Depreciation Rs m2583,851 6.7%   
Interest Rs m-26615 -4.2%   
Profit before tax Rs m1,2165,887 20.7%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,569 21.8%   
Profit after tax Rs m8064,531 17.8%  
Gross profit margin %24.020.1 119.3%  
Effective tax rate %28.126.7 105.6%   
Net profit margin %13.511.0 123.0%  
BALANCE SHEET DATA
Current assets Rs m5,10241,486 12.3%   
Current liabilities Rs m2,38521,413 11.1%   
Net working cap to sales %45.648.7 93.6%  
Current ratio x2.11.9 110.4%  
Inventory Days Days15064 234.6%  
Debtors Days Days11394 120.3%  
Net fixed assets Rs m5,14850,661 10.2%   
Share capital Rs m1583,000 5.3%   
"Free" reserves Rs m6,55648,808 13.4%   
Net worth Rs m6,73251,808 13.0%   
Long term debt Rs m95217,898 5.3%   
Total assets Rs m10,38899,897 10.4%  
Interest coverage x-45.810.6 -433.0%   
Debt to equity ratio x0.10.3 40.9%  
Sales to assets ratio x0.60.4 139.1%   
Return on assets %7.55.2 145.7%  
Return on equity %12.08.7 136.9%  
Return on capital %14.69.6 151.6%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29812,058 43.9%   
Fx outflow Rs m1,7727,348 24.1%   
Net fx Rs m3,5254,710 74.8%   
CASH FLOW
From Operations Rs m1,2746,621 19.2%  
From Investments Rs m-1,204-6,840 17.6%  
From Financial Activity Rs m-196-2,397 8.2%  
Net Cashflow Rs m-126-2,612 4.8%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 81.0 20.6 393.2%  
Indian inst/Mut Fund % 0.3 8.4 3.6%  
FIIs % 9.6 10.7 89.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.9 45.7%  
Shareholders   42,599 109,995 38.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (4QFY18); Net Profit Up 19.8% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 19.8% YoY). Sales on the other hand came in at Rs 12 bn (up 25.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - ALEMBIC PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS